In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans.
about
Bedaquiline for the treatment of multidrug-resistant tuberculosis: great promise or disappointment?Current treatment of atypical mycobacteriosisActivities of rifampin, Rifapentine and clarithromycin alone and in combination against mycobacterium ulcerans disease in miceDiarylquinolines target subunit c of mycobacterial ATP synthaseRapid, serial, non-invasive assessment of drug efficacy in mice with autoluminescent Mycobacterium ulcerans infectionPentacyclic nitrofurans with in vivo efficacy and activity against nonreplicating Mycobacterium tuberculosisMycobacterium ulcerans in the Elderly: More Severe Disease and Suboptimal OutcomesSterilizing Activity of Fully Oral Intermittent Regimens against Mycobacterium Ulcerans Infection in MiceComparative Study of Activities of a Diverse Set of Antimycobacterial Agents against Mycobacterium tuberculosis and Mycobacterium ulceransAll-oral antibiotic treatment for buruli ulcer: a report of four patients.A Review of the Evidence for Using Bedaquiline (TMC207) to Treat Multi-Drug Resistant TuberculosisRapid assessment of antibacterial activity against Mycobacterium ulcerans by using recombinant luminescent strains.The chemical biology of new drugs in the development for tuberculosis.Successful outcomes with oral fluoroquinolones combined with rifampicin in the treatment of Mycobacterium ulcerans: an observational cohort studyIncidence, clinical spectrum, diagnostic features, treatment and predictors of paradoxical reactions during antibiotic treatment of Mycobacterium ulcerans infections.Mycobacterium leprae is naturally resistant to PA-824Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration.Combined inflammatory and metabolic defects reflected by reduced serum protein levels in patients with Buruli ulcer diseaseImpact of Fgd1 and ddn diversity in Mycobacterium tuberculosis complex on in vitro susceptibility to PA-824.Treating Mycobacterium ulcerans disease (Buruli ulcer): from surgery to antibiotics, is the pill mightier than the knife?Curing Mycobacterium ulcerans infection in mice with a combination of rifampin-streptomycin or rifampin-amikacin.Chemotherapy-associated changes of histopathological features of Mycobacterium ulcerans lesions in a Buruli ulcer mouse model.Orally administered combined regimens for treatment of Mycobacterium ulcerans infection in mice.Promising clinical efficacy of streptomycin-rifampin combination for treatment of buruli ulcer (Mycobacterium ulcerans disease)Leveraging Advances in Tuberculosis Diagnosis and Treatment to Address Nontuberculous Mycobacterial DiseaseIn vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis complex isolated in Taiwan over 10 years.Bactericidal and sterilizing activities of several orally administered combined regimens against Mycobacterium ulcerans in miceAmikacin-induced Fin Reduction is Mediated by AutophagyImpact of the interaction of R207910 with rifampin on the treatment of tuberculosis studied in the mouse model.Impacts of dosing frequency of the combination rifampin-streptomycin on its bactericidal and sterilizing activities against Mycobacterium ulcerans in miceSusceptibility Profiles of Mycobacterium ulcerans Isolates to Streptomycin and Rifampicin in Two Districts of the Eastern Region of Ghana.TMC207 becomes bedaquiline, a new anti-TB drug.Management of BU-HIV co-infection.Antibiotic Complications During the Treatment of Mycobacterium ulcerans Disease in Australian Patients.Bedaquiline inhibits the ATP synthase in Mycobacterium abscessus and is effective in infected zebrafish.Plasma disposition of conventional and long-acting moxifloxacin in sheep after intravenous administration.Pharmacokinetics and tissue residues of moxifloxacin in broiler chickens.Buruli Ulcer, a Prototype for Ecosystem-Related Infection, Caused by Mycobacterium ulcerans.Adhesion of the ulcerative pathogen Mycobacterium ulcerans to DACC-coated dressings.
P2860
Q26824413-5EB39144-6DB0-45BD-A43A-EA1DD1BCB2A6Q28265322-0F755975-A548-4B34-838C-1C058C8E6F6EQ28476689-292E85EB-917B-47DF-A9FF-37883D8757BFQ28486434-6898FC24-C427-486D-8CB1-EC548C210073Q28537749-16BA0BDF-8E47-43CA-8BF5-2BF3C82AF2E1Q28539526-E4E2AD5D-727C-419F-BAEF-23FFDBA10521Q28551237-4AF7BDA7-CA0D-41BD-8D85-968A4017A393Q28552736-1DCD2FC4-1D23-446E-9660-4B2CCC0B88CAQ28833171-6C3F014C-B4AA-47F0-BC21-75E2D1ED34C3Q33769921-0A3A011F-583C-4A2E-95D5-AA57F6C04254Q33939074-7A72F113-F9BC-417D-962A-E6662E8AC02AQ33962755-624A2120-2D12-4BE2-8006-49D727039463Q34054325-DD2F4335-7267-416F-BFAC-0B7970F90C52Q34137837-BE532442-3A96-450D-8C94-35D56762431DQ34978950-3C15F0CE-ADDB-450F-A771-3F4485674806Q35091589-EE2E2ECE-F05E-495E-BD6D-C8B4BD4F2126Q35127770-704D8389-F908-4B95-BED1-C4C4BC569BA0Q35145483-2885D331-B917-414C-A219-0133BD0F4FEBQ35598383-127DE059-D895-46D6-A5D9-8D49AAE02E18Q35625819-ACEA54BA-68BB-4217-97B9-33CED791CC07Q35635900-9834C0B4-1251-4804-94EF-EC06D628BF5AQ35689285-0F12DEBE-1326-43B9-97C3-EF102F9BE503Q36095055-843D0AD2-F93A-44BE-926B-CA9F56552148Q36295353-0BAF8B74-D505-40A5-9123-3A416D1BC697Q36617120-E4B731D0-BF9B-41C6-B5EC-46397914E0F8Q36703055-36EDCC51-068D-46DA-AEE8-3005F1376BB0Q36703065-5A0C74A2-FDCF-4614-9C27-934F727504F4Q36749859-95EAC9F8-C801-461D-99CD-BE15F58081F9Q36932992-7B7623BA-7A3C-43F9-9153-FD7CF33C416CQ37247677-5EE5CAD0-B165-4C9A-9B2B-6DE770F57A1FQ37539074-0E2F2342-D710-4B4B-8D2D-FFCA28E50AFFQ38135901-683734BF-ED70-4B94-93F0-181F20090398Q38221645-352EDC23-E12A-490E-993D-A766A5630F49Q38741481-D16BDE07-A99D-45B2-AAF0-F0520FFC31B1Q40093529-64355F54-691B-42A4-9241-E23D3EC5362CQ40843546-7F26259B-E5EC-4653-A00E-05569FD7668CQ46047517-98BEF964-6C15-4C4B-BDA8-F05667F19F9AQ46241939-6348956F-E227-45E1-B299-AA92F02812B8Q53469363-1196B9B2-68E3-4D31-8D48-CC3C797CCB21
P2860
In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
In vitro and in vivo activitie ...... gainst Mycobacterium ulcerans.
@ast
In vitro and in vivo activitie ...... gainst Mycobacterium ulcerans.
@en
In vitro and in vivo activitie ...... gainst Mycobacterium ulcerans.
@nl
type
label
In vitro and in vivo activitie ...... gainst Mycobacterium ulcerans.
@ast
In vitro and in vivo activitie ...... gainst Mycobacterium ulcerans.
@en
In vitro and in vivo activitie ...... gainst Mycobacterium ulcerans.
@nl
prefLabel
In vitro and in vivo activitie ...... gainst Mycobacterium ulcerans.
@ast
In vitro and in vivo activitie ...... gainst Mycobacterium ulcerans.
@en
In vitro and in vivo activitie ...... gainst Mycobacterium ulcerans.
@nl
P2093
P2860
P356
P1476
In vitro and in vivo activitie ...... against Mycobacterium ulcerans
@en
P2093
Aurélie Chauffour
Baohong Ji
Chantal Truffot
Sébastien Lefrançois
Vincent Jarlier
P2860
P304
P356
10.1128/AAC.00052-06
P407
P577
2006-06-01T00:00:00Z